Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Travoprost/timolol

Drug Profile

Travoprost/timolol

Alternative Names: 0.004% travoprost/0.5% timolol; DuoTrav; DuoTrav APS; DuoTrav® PQ; DuoTrav™ BAK; Extravan; Timolol/travoprost; Travoprost + Timolol Fixed Combination; TTFC

Latest Information Update: 15 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon
  • Developer Alcon; Novartis
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Thiadiazoles
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma

Most Recent Events

  • 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
  • 27 Jan 2017 Novartis has patent protection for travoprost/timolol in Europe and Japan (Novartis 20-F filed in 2017)
  • 13 Apr 2015 No recent reports on development identified - Preregistration for Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top